{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:48:33Z","timestamp":1776779313033,"version":"3.51.2"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010226","name":"Guangdong Province Department of Education","doi-asserted-by":"publisher","award":["2024KTSCX169"],"award-info":[{"award-number":["2024KTSCX169"]}],"id":[{"id":"10.13039\/501100010226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["202201010035"],"award-info":[{"award-number":["202201010035"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.bbrc.2025.151971","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T17:09:11Z","timestamp":1746724151000},"page":"151971","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Connectivity-map unveils Gemcitabine's efficacy in overcoming nelarabine resistance in T-cell acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"769","author":[{"family":"Ximei Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunxu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suchang","family":"chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zitao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luyong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5112-7288","authenticated-orcid":false,"given":"Min","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bbrc.2025.151971_bib1","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.bbrc.2025.151971_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-023-00853-3","article-title":"Global burden of hematologic malignancies and evolution patterns over the past 30 years","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J."},{"issue":"10230","key":"10.1016\/j.bbrc.2025.151971_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bbrc.2025.151971_bib4","doi-asserted-by":"crossref","DOI":"10.1182\/asheducation-2016.1.580","article-title":"T-cell acute lymphoblastic leukemia","volume":"2016","author":"Raetz","year":"2016","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.bbrc.2025.151971_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-022-00613-9","article-title":"Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins","volume":"12","author":"Steiml\u00e9","year":"2022","journal-title":"Blood Cancer J."},{"issue":"12","key":"10.1016\/j.bbrc.2025.151971_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25957","article-title":"Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed\/refractory T\u2010cell acute lymphoblastic leukemia\/lymphoma. A CAMPUS ALL study","volume":"95","author":"Candoni","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"8","key":"10.1016\/j.bbrc.2025.151971_bib7","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2011-02-337840","article-title":"In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia","volume":"118","author":"Homminga","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bbrc.2025.151971_bib8","doi-asserted-by":"crossref","DOI":"10.1345\/aph.1E453","article-title":"Nelarabine: a nucleoside analog with efficacy in T-Cell and other leukemias","volume":"39","author":"Kisor","year":"2005","journal-title":"Ann. Pharmacother."},{"issue":"1","key":"10.1016\/j.bbrc.2025.151971_bib9","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2023010303","article-title":"Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia","volume":"8","author":"Shimony","year":"2024","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.bbrc.2025.151971_bib10","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2003-01-0317","article-title":"Mechanisms for T-cell selective cytotoxicity of arabinosylguanine","volume":"102","author":"Rodriguez","year":"2003","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bbrc.2025.151971_bib11","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-022-04880-1","article-title":"Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis","volume":"101","author":"Kathpalia","year":"2022","journal-title":"Ann. Hematol."},{"issue":"7","key":"10.1016\/j.bbrc.2025.151971_bib12","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2022008280","article-title":"Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma\/leukemia","volume":"7","author":"Shimony","year":"2023","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.bbrc.2025.151971_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2141.2007.06527.x","article-title":"In Vitro cytotoxicity of nelarabine, clofarabine and flavopiridol in paediatric acute lymphoblastic leukaemia","volume":"137","author":"Beesley","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bbrc.2025.151971_bib14","article-title":"Cross-resistance among sequential cancer therapeutics: an emerging issue","volume":"12","author":"Loria","year":"2022","journal-title":"Front. Oncol."},{"issue":"21","key":"10.1016\/j.bbrc.2025.151971_bib15","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbrc.2025.151971_bib16","article-title":"Clofarabine in the treatment of myelodysplastic syndromes","volume":"23","author":"Bryan","year":"2014","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"23","key":"10.1016\/j.bbrc.2025.151971_bib17","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2008.19.6550","article-title":"Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial","volume":"27","author":"Steensma","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bbrc.2025.151971_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.bbrc.2025.151971_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113098","article-title":"Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment","volume":"42","author":"Yabushita","year":"2023","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.bbrc.2025.151971_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.10.049","article-title":"A next generation connectivity map: L1000 platform and the first 1,000,000 profiles","volume":"171","author":"Subramanian","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2025.151971_bib21","article-title":"Decoding connectivity Map-based drug repurposing for oncotherapy","volume":"vol. 24","author":"Zhao","year":"2023"},{"issue":"41","key":"10.1016\/j.bbrc.2025.151971_bib22","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1501597112","article-title":"Connectivity Map-based discovery of parbendazole reveals targetable human osteogenic pathway","volume":"112","author":"Brum","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"3","key":"10.1016\/j.bbrc.2025.151971_bib23","article-title":"Advances in diagnosis and treatment of T cell acute lymphoblastic leukemia","volume":"44","author":"Yuan","year":"2021","journal-title":"Int. J. Blood Transfus. Hematol."},{"key":"10.1016\/j.bbrc.2025.151971_bib24","article-title":"Allogeneic CD5-specific CAR-T therapy for relapsed\/refractory T-ALL: a phase 1 trial","volume":"1","author":"Pan","year":"2024","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bbrc.2025.151971_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-024-00525-x","article-title":"Acute lymphoblastic leukaemia","volume":"10","author":"Pagliaro","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bbrc.2025.151971_bib26","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-024-06121-z","article-title":"The efficacy and safety of nelarabine in relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis","author":"Shakeel","year":"2025","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.bbrc.2025.151971_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.14874","article-title":"Safety and efficacy of nelarabine in children and young adults with relapsed or refractory t\u2010lineage acute lymphoblastic leukaemia or t\u2010lineage lymphoblastic lymphoma: results of a phase 4 study","volume":"179","author":"Zwaan","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.bbrc.2025.151971_bib28","doi-asserted-by":"crossref","DOI":"10.1080\/13880209.2023.2246500","article-title":"Gemcitabine enhances pharmacokinetic exposure of the major components of Danggui Buxue Decoction in rat via the promotion of intestinal permeability and down-regulation of CYP3A for combination treatment of non-small cell lung cancer","volume":"61","author":"Xu","year":"2023","journal-title":"Pharm. Biol."},{"issue":"1","key":"10.1016\/j.bbrc.2025.151971_bib29","article-title":"Gemcitabine in non-small cell lung cancer (NSCLC)","volume":"18","author":"Manegold","year":"2000","journal-title":"Invest. N. Drugs"},{"issue":"3","key":"10.1016\/j.bbrc.2025.151971_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/genes13030466","article-title":"Recent development of prodrugs of gemcitabine","volume":"13","author":"Pandit","year":"2022","journal-title":"Genes"},{"issue":"1","key":"10.1016\/j.bbrc.2025.151971_bib31","doi-asserted-by":"crossref","DOI":"10.1053\/sonc.2002.31593","article-title":"Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma","volume":"29","author":"Hansen","year":"2002","journal-title":"Semin. Oncol."},{"issue":"3H","key":"10.1016\/j.bbrc.2025.151971_bib32","doi-asserted-by":"crossref","DOI":"10.1053\/sonc.2000.22531","article-title":"Gemcitabine in ovarian cancer","volume":"28","author":"Orlando","year":"2001","journal-title":"Semin. Oncol."},{"issue":"1","key":"10.1016\/j.bbrc.2025.151971_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10188","article-title":"Gemcitabine and doxorubicin in immunostimulatory monophosphoryl lipid A liposomes for treating breast cancer","volume":"6","author":"Wu","year":"2021","journal-title":"Bioeng Transl Med"},{"issue":"1","key":"10.1016\/j.bbrc.2025.151971_bib34","doi-asserted-by":"crossref","DOI":"10.1186\/s40661-017-0053-x","article-title":"A retrospective evaluation of activity of gemcitabine\/platinum regimens in the treatment of recurrent ovarian cancer","volume":"4","author":"Le","year":"2017","journal-title":"Gynecol Oncol Res Pract"},{"issue":"11","key":"10.1016\/j.bbrc.2025.151971_bib35","doi-asserted-by":"crossref","DOI":"10.1007\/s11033-022-07782-7","article-title":"A comprehensive review on methotrexate containing nanoparticles; an appropriate tool for cancer treatment","volume":"49","author":"Shariatifar","year":"2022","journal-title":"Mol. Biol. Rep."},{"issue":"1","key":"10.1016\/j.bbrc.2025.151971_bib36","doi-asserted-by":"crossref","DOI":"10.1007\/s00280-016-3003-0","article-title":"Pharmacokinetics and pharmacogenetics of gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective","volume":"78","author":"Ciccolini","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.151971_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2014.07.041","article-title":"Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer","volume":"741","author":"de Sousa Cavalcante","year":"2014","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.bbrc.2025.151971_bib38","doi-asserted-by":"crossref","DOI":"10.2174\/1381612824999180115103951","article-title":"Colchicine in gout: an update","volume":"24","author":"Pascart","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bbrc.2025.151971_bib39","series-title":"Textbook of Autoinflammation","first-page":"729","article-title":"Colchicine","author":"Ben-Chetrit","year":"2019"},{"issue":"1","key":"10.1016\/j.bbrc.2025.151971_bib40","doi-asserted-by":"crossref","DOI":"10.2174\/0929867323666151117121706","article-title":"Biologic agents and more for the treatment of familial mediterranean fever. The old, the new, and the rare","volume":"23","author":"Portincasa","year":"2015","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.bbrc.2025.151971_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-59215-9","article-title":"Efficient classification of white blood cell leukemia with improved swarm optimization of deep features","volume":"10","author":"Sahlol","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2025.151971_bib42","first-page":"12","article-title":"Leukemic stem cells: from leukemic niche biology to treatment opportunities","volume":"15","author":"Marchand","year":"2021","journal-title":"Front. Immunol."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25006850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25006850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T14:53:52Z","timestamp":1762095232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X25006850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":42,"alternative-id":["S0006291X25006850"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.151971","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Connectivity-map unveils Gemcitabine's efficacy in overcoming nelarabine resistance in T-cell acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.151971","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"151971"}}